Sensome Partners With Asahi Intecc to Develop Next-Generation Clotild Smart Guidewire for Stroke

June 21, 2023—France-based Sensome and Asahi Intecc, headquartered in Japan, announced a collaboration to develop the next-generation Clotild smart guidewire for the treatment of acute ischemic stroke.

The Clotild smart guidewire, which incorporates Sensome’s artificial intelligence (AI)–powered tissue microsensor, will provide critical information about clot features, enabling more informed decisions during the procedure. Asahi Intecc will manufacture the device.

Franz Bozsak, CEO of Sensome, commented in the press release, “We are thrilled about our alliance with Asahi Intecc. Marrying Sensome’s unique sensor technology with Asahi Intecc’s exceptional guidewire design, we are pushing the boundaries of medical technology, with the potential to profoundly impact patient outcomes worldwide.

“This collaboration underscores our dedication to pioneering smart medical devices designed to address the present shortcomings of minimally invasive procedures in partnership with world-class medical device manufacturers.”

Masahiko Miyata, CEO of Asahi Intecc, added, “We believe that Sensome’s innovative AI-powered sensing technology will generate significant positive impact on acute ischemic stroke procedures worldwide, and will contribute to better patient outcomes and quality of life. By combining Asahi’s guidewire design and manufacturing technology and experience with Sensome’s core competencies, the companies position themselves to create a new generation of smart guidewires at a high level of performance, reliability, and consequently, value to physicians and patients.”

As noted in the press release, Sensome’s sensor technology combines impedance-based microsensors with machine-learning algorithms to identify biological tissues in real-time. Sensome’s flagship product, the Clotild smart guidewire system, is a connected neurovascular guidewire designed to provide blood clot characterization during the endovascular management of acute ischemic stroke. Clotild is currently being evaluated in a clinical trial.

The company announced the commencement of the CLOT OUT first-in-human study of the Clotild device in September 2021. The company noted that Sensome’s tissue sensing technology has the potential for integration into minimally invasive medical devices used in other areas of treatment such as peripheral vascular disease and oncology.

Sensome is a spin-off from CNRS—France’s Centre National de la Recherche Scientifique—and Ecole Polytechnique in Paris, France.